Novel Metformin Indications and Skin Disorders

Ramadan S. Hussein, Walid Kamal Abdelbasset, Osama Mahfouz

International Journal of Biomedicine. 2022;12(4):521-525.
DOI: 10.21103/Article12(4)_RA4
Originally published December 5, 2022


Metformin is the first-line medication to increase insulin sensitivity in insulin-resistant conditions such as type 2 diabetes, polycystic ovary syndrome, and obesity. However, metformin is a drug with a wide range of pharmacological properties, showing the ability to treat various skin conditions. Some inflammatory skin dermatoses, skin neoplasms, endocrinology-related dermatosis, pigmentary disorders, skin aging, and wound healing have all shown improvement when metformin is used. This review discusses the most recent research supporting the use of metformin as a treatment for common skin conditions.

Metformin • indications • skin disorders

1. Napolitano M, Megna M, Monfrecola G. Insulin resistance and skin diseases. ScientificWorldJournal. 2015;2015:479354. doi: 10.1155/2015/479354.
2. Sawaya M. Antiandrogens and androgen inhibitors. In: Se W, editor. Comprehensive Dermatologic Drug Therapy. Philadelphia: W.B. Saunders Co.; 2001:385 401.
3. Brauchli YB, Jick SS, Curtin F, Meier CR. Association between use of thiazolidinediones or other oral antidiabetics and psoriasis: A population based case-control study. J Am Acad Dermatol. 2008 Mar;58(3):421-9. doi: 10.1016/j.jaad.2007.11.023.
4. Gong L, Goswami S, Giacomini KM, Altman RB, Klein TE. Metformin pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2012 Nov;22(11):820-7. doi: 10.1097/FPC.0b013e3283559b22.
5. Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, Furlong TJ, Greenfield JR, Greenup LC, Kirkpatrick CM, Ray JE, Timmins P, Williams KM. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011 Feb;50(2):81-98. doi: 10.2165/11534750-000000000-00000.
6. Williams HC, Dellavalle RP, Garner S. Acne vulgaris. Lancet. 2012 Jan 28;379(9813):361-72. doi: 10.1016/S0140-6736(11)60321-8. Epub 2011 Aug 29. Erratum in: Lancet. 2012 Jan 28;379(9813):314.
7. Gupta A, Sharma YK, Dash KN, Chaudhari ND, Jethani S. Quality of life in acne vulgaris: Relationship to clinical severity and demographic data. Indian J Dermatol Venereol Leprol. 2016 May-Jun;82(3):292-7. doi: 10.4103/0378-6323.173593.
8. Makrantonaki E, Zouboulis CC. Testosterone metabolism to 5alpha-dihydrotestosterone and synthesis of sebaceous lipids is regulated by the peroxisome proliferator-activated receptor ligand linoleic acid in human sebocytes. Br J Dermatol. 2007 Mar;156(3):428-32. doi: 10.1111/j.1365-2133.2006.07671.x.
9. Del Prete M, Mauriello MC, Faggiano A, Di Somma C, Monfrecola G, Fabbrocini G, Colao A. Insulin resistance and acne: a new risk factor for men? Endocrine. 2012 Dec;42(3):555-60. doi: 10.1007/s12020-012-9647-6.
10. Kartal D, Yildiz H, Ertas R, Borlu M, Utas S. Association between isolated female acne and insulin resistance: a prospective study. G Ital Dermatol Venereol. 2016 Aug;151(4):353-7.
11. Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. Diabetologia. 2017 Sep;60(9):1577-1585. doi: 10.1007/s00125-017-4342-z. E
12. Sawaya M. Antiandrogens and androgen inhibitors. In: Se W, editor. Comprehensive Dermatologic Drug Therapy. Philadelphia: W.B. Saunders Co.; 2001:385 401.
13. Bhambri S, Del Rosso JQ, Bhambri A. Pathogenesis of acne vulgaris: recent advances. J Drugs Dermatol. 2009 Jul;8(7):615-8.
14. Kelly CJ, Gordon D. The effect of metformin on hirsutism in polycystic ovary syndrome. Eur J Endocrinol. 2002 Aug;147(2):217-21. doi: 10.1530/eje.0.1470217.
15. Melnik BC, Schmitz G. Role of insulin, insulin-like growth factor-1, hyperglycaemic food and milk consumption in the pathogenesis of acne vulgaris. Exp Dermatol. 2009 Oct;18(10):833-41. doi: 10.1111/j.1600-0625.2009.00924.x. E
16. Danby FW, Jemec GB, Marsch WCh, von Laffert M. Preliminary findings suggest hidradenitis suppurativa may be due to defective follicular support. Br J Dermatol. 2013 May;168(5):1034-9. doi: 10.1111/bjd.12233.
17. Verdolini R, Clayton N, Smith A, Alwash N, Mannello B. Metformin for the treatment of hidradenitis suppurativa: a little help along the way. J Eur Acad Dermatol Venereol. 2013 Sep;27(9):1101-8. doi: 10.1111/j.1468-3083.2012.04668.x.
18. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007 Jul 21;370(9583):263-271. doi: 10.1016/S0140-6736(07)61128-3.
19. Mihaylova MM, Shaw RJ. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol. 2011 Sep 2;13(9):1016-23. doi: 10.1038/ncb2329.
20. Glossmann H, Reider N. A marriage of two "Methusalem" drugs for the treatment of psoriasis?: Arguments for a pilot trial with metformin as add-on for methotrexate. Dermatoendocrinol. 2013 Apr 1;5(2):252-63. doi: 10.4161/derm.23874.
21. Kaminski MM, Sauer SW, Klemke CD, Süss D, Okun JG, Krammer PH, Gülow K. Mitochondrial reactive oxygen species control T cell activation by regulating IL-2 and IL-4 expression: mechanism of ciprofloxacin-mediated immunosuppression. J Immunol. 2010 May 1;184(9):4827-41. doi: 10.4049/jimmunol.0901662.
22. Krysiak R, Okopien B. Lymphocyte-suppressing and systemic anti-inflammatory effects of high-dose metformin in simvastatin-treated patients with impaired fasting glucose. Atherosclerosis. 2012 Dec;225(2):403-7. doi: 10.1016/j.atherosclerosis.2012.09.034.
23. Li W, Ma W, Zhong H, Liu W, Sun Q. Metformin inhibits proliferation of human keratinocytes through a mechanism associated with activation of the MAPK signaling pathway. Exp Ther Med. 2014 Feb;7(2):389-392. doi: 10.3892/etm.2013.1416.
24. Liu Y, Yang F, Ma W, Sun Q. Metformin inhibits proliferation and proinflammatory cytokines of human keratinocytes in vitro via mTOR-signaling pathway. Pharm Biol. 2016 Jul;54(7):1173-8. doi: 10.3109/13880209.2015.1057652.
25. Hadi NR, Al-Amran FG, Swadi A. Metformin ameliorates methotrexate-induced hepatotoxicity. J Pharmacol Pharmacother. 2012 Jul;3(3):248-53. doi: 10.4103/0976-500X.99426.
26. Sadik CD, Schmidt E, Zillikens D, Hashimoto T. Recent progresses and perspectives in autoimmune bullous diseases. J Allergy Clin Immunol. 2020 Apr;145(4):1145-1147. doi: 10.1016/j.jaci.2020.02.020.
27. Egami S, Yamagami J, Amagai M. Autoimmune bullous skin diseases, pemphigus and pemphigoid. J Allergy Clin Immunol. 2020 Apr;145(4):1031-1047. doi: 10.1016/j.jaci.2020.02.013.
28. Sadik CD, Miyabe Y, Sezin T, Luster AD. The critical role of C5a as an initiator of neutrophil-mediated autoimmune inflammation of the joint and skin. Semin Immunol. 2018 Jun;37:21-29. doi: 10.1016/j.smim.2018.03.002.
29. Patel CH, Leone RD, Horton MR, Powell JD. Targeting metabolism to regulate immune responses in autoimmunity and cancer. Nat Rev Drug Discov. 2019 Sep;18(9):669-688. doi: 10.1038/s41573-019-0032-5.
30. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J. 2000 Jun 15;348 Pt 3(Pt 3):607-14.
31. Kibsgaard L, Rasmussen M, Lamberg A, Deleuran M, Olesen AB, Vestergaard C. Increased frequency of multiple sclerosis among patients with bullous pemphigoid: a population-based cohort study on comorbidities anchored around the diagnosis of bullous pemphigoid. Br J Dermatol. 2017 Jun;176(6):1486-1491. doi: 10.1111/bjd.15405.
32. Seelig E, Meyer S, Timper K, Nigro N, Bally M, Pernicova I, Schuetz P, Müller B, Korbonits M, Christ-Crain M. Metformin prevents metabolic side effects during systemic glucocorticoid treatment. Eur J Endocrinol. 2017 Mar;176(3):349-358. doi: 10.1530/EJE-16-0653.
33. Liu X, Sun Z, Wang H. Metformin alleviates experimental colitis in mice by up-regulating TGF-β signaling. Biotech Histochem. 2021 Feb;96(2):146-152. doi: 10.1080/10520295.2020.1776896.
34. Ursini F, Russo E, Pellino G, D'Angelo S, Chiaravalloti A, De Sarro G, Manfredini R, De Giorgio R. Metformin and Autoimmunity: A "New Deal" of an Old Drug. Front Immunol. 2018 Jun 4;9:1236. doi: 10.3389/fimmu.2018.01236.
35. Kulkarni U, Karsten CM, Kohler T, Hammerschmidt S, Bommert K, Tiburzy B, et al. IL-10 mediates plasmacytosis-associated immunodeficiency by inhibiting complement-mediated neutrophil migration. J Allergy Clin Immunol. 2016 May;137(5):1487-1497.e6. doi: 10.1016/j.jaci.2015.10.018.
36. Sezin T, Krajewski M, Wutkowski A, Mousavi S, Chakievska L, Bieber K, et al. The Leukotriene B4 and its Receptor BLT1 Act as Critical Drivers of Neutrophil Recruitment in Murine Bullous Pemphigoid-Like Epidermolysis Bullosa Acquisita. J Invest Dermatol. 2017 May;137(5):1104-1113. doi: 10.1016/j.jid.2016.12.021.
37. Reddi A, Powers MA, Dellavalle RP. Therapeutic potential of the anti-diabetic agent metformin in targeting the skin cancer stem cell diaspora. Exp Dermatol. 2014 May;23(5):345-6. doi: 10.1111/exd.12349.
38. Sikka A, Kaur M, Agarwal C, Deep G, Agarwal R. Metformin suppresses growth of human head and neck squamous cell carcinoma via global inhibition of protein translation. Cell Cycle. 2012 Apr 1;11(7):1374-82. doi: 10.4161/cc.19798.
39. Cerezo M, Tichet M, Abbe P, Ohanna M, Lehraiki A, Rouaud F, et al. Metformin blocks melanoma invasion and metastasis development in AMPK/p53-dependent manner. Mol Cancer Ther. 2013 Aug;12(8):1605-15. doi: 10.1158/1535-7163.MCT-12-1226-T.
40. Chaudhary SC, Kurundkar D, Elmets CA, Kopelovich L, Athar M. Metformin, an antidiabetic agent reduces growth of cutaneous squamous cell carcinoma by targeting mTOR signaling pathway. Photochem Photobiol. 2012 Sep-Oct;88(5):1149-56. doi: 10.1111/j.1751-1097.2012.01165.x.
41. Iliopoulos D, Hirsch HA, Wang G, Struhl K. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1397-402. doi: 10.1073/pnas.1018898108.
42. Hirsch HA, Iliopoulos D, Struhl K. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc Natl Acad Sci U S A. 2013 Jan 15;110(3):972-7. doi: 10.1073/pnas.1221055110.
43. Iliopoulos D, Hirsch HA, Struhl K. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. Cancer Res. 2011 May 1;71(9):3196-201. doi: 10.1158/0008-5472.CAN-10-3471.
44. Martin MJ, Hayward R, Viros A, Marais R. Metformin accelerates the growth of BRAF V600E-driven melanoma by upregulating VEGF-A. Cancer Discov. 2012 Apr;2(4):344-55. doi: 10.1158/2159-8290.CD-11-0280.
45. Kelly CJ, Gordon D. The effect of metformin on hirsutism in polycystic ovary syndrome. Eur J Endocrinol. 2002 Aug;147(2):217-21. doi: 10.1530/eje.0.1470217.
46. Ibáñez L, López-Bermejo A, Díaz M, Marcos MV, de Zegher F. Early metformin therapy (age 8-12 years) in girls with precocious pubarche to reduce hirsutism, androgen excess, and oligomenorrhea in adolescence. J Clin Endocrinol Metab. 2011 Aug;96(8):E1262-7. doi: 10.1210/jc.2011-0555.
47. Rezvanian H, Adibi N, Siavash M, Kachuei A, Shojaee-Moradie F, Asilian A. Increased insulin sensitivity by metformin enhances intense-pulsed-light-assisted hair removal in patients with polycystic ovary syndrome. Dermatology. 2009;218(3):231-6. doi: 10.1159/000187718.
48. Phiske MM. An approach to acanthosis nigricans. Indian Dermatol Online J. 2014 Jul;5(3):239-49. doi: 10.4103/2229-5178.137765.
49. Hermanns-Lê T, Scheen A, Piérard GE. Acanthosis nigricans associated with insulin resistance : pathophysiology and management. Am J Clin Dermatol. 2004;5(3):199-203. doi: 10.2165/00128071-200405030-00008.
50. Walling HW, Messingham M, Myers LM, Mason CL, Strauss JS. Improvement of acanthosis nigricans on isotretinoin and metformin. J Drugs Dermatol. 2003 Dec;2(6):677-81.
51. Atabek ME, Pirgon O. Use of metformin in obese adolescents with hyperinsulinemia: a 6-month, randomized, double-blind, placebo-controlled clinical trial. J Pediatr Endocrinol Metab. 2008 Apr;21(4):339-48. doi: 10.1515/jpem.2008.21.4.339.
52. Barbato MT, Criado PR, Silva AK, Averbeck E, Guerine MB, Sá NB. Association of acanthosis nigricans and skin tags with insulin resistance. An Bras Dermatol. 2012 Jan-Feb;87(1):97-104. doi: 10.1590/s0365-05962012000100012.
53. Belisle ES, Park HY. Metformin: a potential drug to treat hyperpigmentation disorders. J Invest Dermatol. 2014 Oct;134(10):2488-2491. doi: 10.1038/jid.2014.245.
54. Park HY, Lee J, González S, Middelkamp-Hup MA, Kapasi S, Peterson S, Gilchrest BA. Topical application of a protein kinase C inhibitor reduces skin and hair pigmentation. J Invest Dermatol. 2004 Jan;122(1):159-66. doi: 10.1046/j.0022-202X.2003.22134.x.
55. Batchuluun B, Inoguchi T, Sonoda N, Sasaki S, Inoue T, Fujimura Y, Miura D, Takayanagi R. Metformin and liraglutide ameliorate high glucose-induced oxidative stress via inhibition of PKC-NAD(P)H oxidase pathway in human aortic endothelial cells. Atherosclerosis. 2014 Jan;232(1):156-64. doi: 10.1016/j.atherosclerosis.2013.10.025.
56. Lehraiki A, Abbe P, Cerezo M, Rouaud F, Regazzetti C, Chignon-Sicard B, Passeron T, Bertolotto C, Ballotti R, Rocchi S. Inhibition of melanogenesis by the antidiabetic metformin. J Invest Dermatol. 2014 Oct;134(10):2589-2597. doi: 10.1038/jid.2014.202.

Download Article
Received October 31, 2022.
Accepted December 2, 2022.
©2022 International Medical Research and Development Corporation.